1. Home
  2. MRCC vs INBX Comparison

MRCC vs INBX Comparison

Compare MRCC & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monroe Capital Corporation

MRCC

Monroe Capital Corporation

HOLD

Current Price

$6.71

Market Cap

151.2M

Sector

Finance

ML Signal

HOLD

Logo Inhibrx Inc.

INBX

Inhibrx Inc.

HOLD

Current Price

$80.18

Market Cap

430.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRCC
INBX
Founded
2011
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.2M
430.2M
IPO Year
2012
2020

Fundamental Metrics

Financial Performance
Metric
MRCC
INBX
Price
$6.71
$80.18
Analyst Decision
Hold
Hold
Analyst Count
1
2
Target Price
$8.00
N/A
AVG Volume (30 Days)
102.5K
236.0K
Earning Date
11-05-2025
11-14-2025
Dividend Yield
15.02%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$43,742,000.00
$1,400,000.00
Revenue This Year
N/A
$563.00
Revenue Next Year
N/A
$230.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.86
$10.81
52 Week High
$8.85
$94.47

Technical Indicators

Market Signals
Indicator
MRCC
INBX
Relative Strength Index (RSI) 55.06 51.68
Support Level $6.65 $79.00
Resistance Level $6.80 $94.47
Average True Range (ATR) 0.14 6.11
MACD 0.06 -1.56
Stochastic Oscillator 81.30 12.77

Price Performance

Historical Comparison
MRCC
INBX

About MRCC Monroe Capital Corporation

Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.

About INBX Inhibrx Inc.

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Share on Social Networks: